32.03
+2.53%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IDEAYA Biosciences
From its filings with the US Securities and Exchange Commission
IDEAYA Biosciences is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IDYA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $218.7m and a net loss of $113.7m. At that date it held total assets of $1.11bn and shareholders' equity of $1.02bn.
We are a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Our clinical development strategy is to evaluate our product candidates in rational combinations, where appropriate, and earlier in the course of disease in the adjuvant and neoadjuvant settings, which we believe has the potential to maximize their impact. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Quoted from its 10-K, filed 17 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 May 2019
- Employees
- 145
- Website
- ideayabio.com ↗
- Head office
- 5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Terry RosenIndependent Chairman of the Board$495,168
- Mr. Yujiro HataPresident, Chief Executive Officer, Director, since 2015$16.9m
- Dr. Joshua BleharskiChief Financial Officer
- Mr. Andres BrisenoChief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations$3.4m
- Dr. Michael WhiteChief Scientific Officer$5.4m
- Dr. Darrin BeaupreChief Medical Officer$6.1m
- Mr. Stuart DormanChief Commercial Officer$3.4m
- Dr. M. Garret HamptonIndependent Director$452,668
- Dr. Catherine MackeyIndependent Director$455,168
- Mr. Scott MorrisonIndependent Director$472,668
- Dr. Jeffrey SteinIndependent Director$472,668
- Ms. Wendy YarnoIndependent Director$465,168
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 49
- Social
- 54
- Governance
- 35
- Women in the workforce
- 46%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IDEAYA Biosciences Inc possesses several strengths that contribute to its competitive advantage and potential success in the biotechnology industry. These strengths include:
Weaknesses
- Despite its strengths, IDEAYA Biosciences Inc also faces certain weaknesses that could pose challenges to its growth and competitiveness:
Opportunities
- IDEAYA Biosciences Inc has several opportunities to maximize its growth potential and expand its market presence:
Threats
- IDEAYA Biosciences Inc should be mindful of potential threats that could impact its performance and disrupt its strategic objectives:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.